We could show that epigenetic editing of RASSF10 is possible, and one could think of targeted therapies in the future using virally applied CRISPR-Cas9 Epigenetic Editors to patients for reactivation of e.g. hypermethylated RASSF10 specifically in cancer (Fig. 4). This evidence concerns the gene RASSF10 and cancer.